FIGO 2026 Gestational Trophoblastic Neoplasia
Reading File
Finding Sources
Searching the Web
FIGO 2026 gestational trophoblastic neoplasia staging classification update
Searching PubMed
gestational trophoblastic neoplasia FIGO staging 2026
Reading Web Page
https://cdn-links.lww.com/permalink/aog/e/aog_147_4_2026_01_…
Reading File
Searching PubMed
gestational trophoblastic neoplasia staging scoring 2026
Reading Article
PMID: 42473063
Finding Sources
Searching the Web
FIGO 2026 GTN staging changes "new" OR "updated" WHO prognostic score modifications
Reading Web Page
https://www.figo.org/news/figo-updates-gestational-trophobla…
Reading File
I now have sufficient information to compile a comprehensive answer. The key finding from FIGO's own website is that the 2026 revision introduces a new ultra-high-risk category alongside low-risk and high-risk groups. The paper was published July 19, 2026 (PMID 42473063) by Ngan HYS, Seckl MJ, Horowitz N et al. Let me now provide the full comprehensive response.
FIGO 2026 Gestational Trophoblastic Neoplasia: Staging & Scoring System
The FIGO 2026 GTN staging and scoring system was published on July 19, 2026 in the International Journal of Gynaecology and Obstetrics (Ngan HYS, Seckl MJ, Horowitz N, et al. FIGO staging for gestational trophoblastic neoplasia: 2026, PMID 42473063). This replaces the previous 2000/2002 FIGO system and represents the most significant update in over two decades.
What Is GTN?
Gestational trophoblastic neoplasia (GTN) encompasses:
- Invasive mole (most common, post-molar)
- Choriocarcinoma (highly malignant, highly chemosensitive)
- Placental site trophoblastic tumor (PSTT) (rare, hCG-poor, surgery-dependent)
- Epithelioid trophoblastic tumor (ETT) (very rare, may resemble cervical squamous carcinoma)
- Post-molar persistent/rising hCG (diagnosed biochemically, no histology required)
GTN remains one of the most curable solid tumors in women, even with distant metastases.
FIGO Diagnosis of GTN (Unchanged in 2026)
GTN is diagnosed by any one of the following criteria:
- Rise in hCG for 3 or more consecutive measurements over at least 2 weeks (e.g., days 1, 7, 14)
- 4 or more plateaued hCG measurements over 3 weeks (days 1, 7, 14, 21)
- Histologic diagnosis of choriocarcinoma
- Elevated hCG for 6 months or longer after uterine evacuation of a molar pregnancy, even if levels are falling
Part 1: FIGO Anatomic Staging (I-IV)
The anatomic staging framework is retained in the 2026 update:
| Stage | Description |
|---|---|
| I | Disease confined to the uterus |
| II | GTN extends outside uterus but limited to genital structures (adnexa, vagina, broad ligament) |
| III | GTN extends to the lungs, with or without known genital tract involvement |
| IV | All other metastatic sites (brain, liver, kidney, spleen, GI tract, etc.) |
Part 2: Modified WHO Prognostic Scoring System (Updated 2026)
The scoring system assigns points to 8 risk factors. The 2026 system retains all prior parameters but redefines the interval boundaries (note the change in month cut-offs compared to older versions):
| Risk Factor | Score 0 | Score 1 | Score 2 | Score 4 |
|---|---|---|---|---|
| Age | < 40 years | ≥ 40 years | - | - |
| Antecedent pregnancy | Mole | Abortion | Term | - |
| Interval from index pregnancy | < 4 months | 4 to < 7 months | 7 to < 13 months | ≥ 13 months |
| Pretreatment serum hCG (IU/L) | < 10³ | 10³ to < 10⁴ | 10⁴ to < 10⁵ | ≥ 10⁵ |
| Largest tumor size (incl. uterus) | - | 3 to < 5 cm | ≥ 5 cm | - |
| Site of metastases | Lung | Spleen, kidney | GI tract | Brain, liver |
| Number of metastases | 0 | 1-4 | 5-8 | > 8 |
| Prior failed chemotherapy | None | - | Single drug | ≥ 2 drugs |
Key interval change vs. prior versions: The prior system used cutoffs of <4, 4-6, 7-12, >12 months. The 2026 system uses <4, 4 to <7, 7 to <13, ≥13 months - a minor but data-driven refinement.
Part 3: The Major 2026 Update - Three Risk Categories
THE HEADLINE CHANGE: Introduction of Ultra-High Risk
The 2026 system creates three risk categories (previously two):
| Category | WHO/FIGO Score | Treatment Implication |
|---|---|---|
| Low risk | ≤ 6 | Single-agent chemotherapy |
| High risk | 7-12 | Multi-agent chemotherapy (EMA-CO) |
| Ultra-high risk | ≥ 13, OR any score with brain/liver/extensive metastases | Modified/induction regimen before standard multi-agent |
Why Ultra-High Risk was Formally Introduced:
In patients with WHO score ≥ 13 or extensive metastatic disease (brain, liver), starting standard first-line multi-agent chemotherapy may cause sudden tumor collapse leading to:
- Severe hemorrhage
- Metabolic acidosis
- Myelosuppression and septicemia
- Multiple organ failure
These patients require low-dose induction chemotherapy (e.g., etoposide + cisplatin) to debulk before full EMA-CO, reducing the risk of catastrophic tumor lysis.
Part 4: Treatment by Risk Category (2026 Guidance)
Low-Risk GTN (Stages I, II, III + score ≤ 6)
- First line: Single-agent chemotherapy - 8-day methotrexate (MTX) 1 mg/kg with folinic acid rescue (most used)
- Resistance to MTX: Actinomycin-D (Act-D) 1.25 mg/m² biweekly bolus, or occasionally carboplatin AUC 6 every 3 weeks
- Resistance to two single agents: Escalate to first-line multi-agent regimen
Predictors of single-agent resistance (2026 data): Pretreatment hCG ≥ 100,000 IU/L (aOR 4.85), metastatic disease (aOR 4.26), WHO/FIGO score 5-6 (aOR 8.13 vs. 0-4)
High-Risk GTN (Score 7-12)
- First line: EMA-CO (etoposide, methotrexate, actinomycin-D alternating with cyclophosphamide and vincristine)
- Resistance or relapse: EMA-EP (cisplatin replaces vincristine/cyclophosphamide in week 2)
- At least 6 weeks maintenance after hCG normalization
Ultra-High-Risk GTN (Score ≥ 13 or brain/liver metastases)
- Induction: Low-intensity etoposide + cisplatin (EP) x 1-2 cycles to reduce tumor burden before EMA-CO
- Then transition to full EMA-CO
- CNS disease may require adjunct whole-brain radiation or intrathecal methotrexate
- Hepatic metastases may require embolization before systemic therapy
Part 5: PSTT and ETT - Special Considerations (Unchanged 2026)
These rare tumors differ fundamentally from choriocarcinoma:
- PSTT/ETT: Relatively chemoresistant, hCG often minimally elevated (HPL more useful for PSTT)
- Treatment: Hysterectomy if uterine-confined; multi-agent platinum-based regimens (EMA-EP) for metastatic disease
- WHO scoring system is not applicable to PSTT/ETT - staging alone guides management
Part 6: Surveillance After Treatment
Following hCG normalization:
- Low-risk GTN: hCG monthly for 12 months post-treatment
- High-risk GTN: hCG monthly for 18-24 months post-treatment
- Contraception mandatory during follow-up (avoid hCG confusion with pregnancy)
- Future pregnancy is not contraindicated after completion of follow-up
Summary of 2026 vs. Prior FIGO System
| Feature | Pre-2026 | 2026 Update |
|---|---|---|
| Risk categories | 2 (low / high) | 3 (low / high / ultra-high) |
| Score cutoffs | Low ≤6, High ≥7 | Low ≤6, High 7-12, Ultra-high ≥13 |
| Interval scoring boundaries | 4-6, 7-12, >12 months | 4 to <7, 7 to <13, ≥13 months |
| Ultra-high risk management | Implied but not formalized | Formally codified with induction approach |
| Anatomic stages | I-IV | I-IV (unchanged) |
| Diagnostic criteria | As per 2002 | Retained |
Source: Ngan HYS, Seckl MJ, Horowitz N, et al. FIGO staging for gestational trophoblastic neoplasia: 2026. Int J Gynaecol Obstet. 2026 Jul 19. PMID: 42473063. Also consistent with Appendix 1, Obstet Gynecol 2026;147 (Paiva G et al.), and FIGO official announcement July 20, 2026.
This is a shared conversation. Sign in to Orris to start your own chat.